Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 1/2003

01-01-2003 | Review Article

Role of P-Glycoprotein in Pharmacokinetics

Clinical Implications

Authors: Dr Jiunn H. Lin, Masayo Yamazaki

Published in: Clinical Pharmacokinetics | Issue 1/2003

Login to get access

Abstract

P-glycoprotein, the most extensively studied ATP-binding cassette (ABC) transporter, functions as a biological barrier by extruding toxins and xenobiotics out of cells. In vitro and in vivo studies have demonstrated that P-glycoprotein plays a significant role in drug absorption and disposition. Because of its localisation, P-glycoprotein appears to have a greater impact on limiting cellular uptake of drugs from blood circulation into brain and from intestinal lumen into epithelial cells than on enhancing the excretion of drugs out of hepatocytes and renal tubules into the adjacent luminal space. However, the relative contribution of intestinal P-glycoprotein to overall drug absorption is unlikely to be quantitatively important unless a very small oral dose is given, or the dissolution and diffusion rates of the drug are very slow. This is because P-glycoprotein transport activity becomes saturated by high concentrations of drug in the intestinal lumen.
Because of its importance in pharmacokinetics, P-glycoprotein transport screening has been incorporated into the drug discovery process, aided by the availability of transgenic mdr knockout mice and in vitro cell systems. When applying in vitro and in vivo screening models to study P-glycoprotein function, there are two fundamental questions: (i) can in vitro data be accurately extrapolated to the in vivo situation; and (ii) can animal data be directly scaled up to humans? Current information from our laboratory suggests that in vivo P-glycoprotein activity for a given drug can be extrapolated reasonably well from in vitro data. On the other hand, there are significant species differences in P-glycoprotein transport activity between humans and animals, and the species differences appear to be substrate-dependent.
Inhibition and induction of P-glycoprotein have been reported as the causes of drug-drug interactions. The potential risk of P-glycoprotein-mediated drug interactions may be greatly underestimated if only plasma concentration is monitored. From animal studies, it is clear that P-glycoprotein inhibition always has a much greater impact on tissue distribution, particularly with regard to the brain, than on plasma concentrations. Therefore, the potential risk of P-glycoprotein-mediated drug interactions should be assessed carefully. Because of overlapping substrate specificity between cytochrome P450 (CYP) 3A4 and P-glycoprotein, and because of similarities in P-glycoprotein and CYP3A4 inhibitors and inducers, many drug interactions involve both P-glycoprotein and CYP3A4. Unless the relative contribution of P-glycoprotein and CYP3A4 to drug interactions can be quantitatively estimated, care should be taken when exploring the underlying mechanism of such interactions.
Literature
1.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152–62PubMed
2.
Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427PubMed
3.
Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Cancer Biol 1997; 8: 161–70
4.
van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507–17PubMed
5.
Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr 2 gene. Cell 1994; 77: 1071–81PubMed
6.
Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000; 275: 23530–9PubMed
7.
Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735–8PubMed
8.
Cordon-Cardo C, O’Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–87PubMed
9.
Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr la P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491–502PubMed
10.
Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028–33PubMed
11.
Chen C-J, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–9PubMed
12.
Loo TW, Clarke DM. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 1994; 269: 7750–5PubMed
13.
Muller M, Bakos E, Welker E, et al. Altered drug-stimulated ATPase activity in mutants of human multidrug resistance protein. J Biol Chem 1996; 271: 1877–83PubMed
14.
Takada Y, Yamada K, Taguchi Y, et al. Non-equivalent cooperation between the two nucleotide binding folds of P-glycoprotein. Biochim Biophys Acta 1998; 1373: 131–6PubMed
15.
Hrycyna CA, Arian LE, Germann UA, et al. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry 1998; 37: 13660–73PubMed
16.
Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155–99PubMed
17.
Homolya L, Hollo Z, Germann UA, et al. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993; 268: 21493–6PubMed
18.
Shapiro AB, Ling V. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 1997; 250: 122–9PubMed
19.
Higgins CF, Gottesman MM. Is the multidrug transporter a flippase?. Trends Biochem Sci 1992; 17: 18–21PubMed
20.
Rosenberg MF, Callaghan R, Ford RC, et al. Structure of multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 1997; 272: 10685–94PubMed
21.
Hung LW, Wang IX, Nikaido K, et al. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 1998; 396: 703–7PubMed
22.
Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–98PubMed
23.
Schurr E, Raymond M, Bell JC, et al. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr cDNA. Cancer Res 1989; 49: 2729–34PubMed
24.
Senior AE, Gadsby DC. ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. Semin Cancer Biol 1997; 8: 143–50PubMed
25.
Shapiro AB, Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur J Biochem 1998; 254: 189–93PubMed
26.
Ambudkar SV, Cardarelli CO, Pashinsky I, et al. Relationship between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 1997; 272: 21160–6PubMed
27.
Greenberger LM. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within or immediately C-terminal to transmembrane domains 6 and 12. J Biol Chem 1993; 268: 11417–25PubMed
28.
Bruggemann EP, Germann UA, Gottesman MM, et al. Two different regions of phosphoglycoprotein are photoaffinity-labeled by azidopine. J Biol Chem 1989; 264: 15483–8PubMed
29.
Wu Q, Bounaud P, Kudul S, et al. Identification of the domains of photoincorporation of the 3′- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdrlb P-glycoprotein. Biochemistry 1998; 37: 11272–9PubMed
30.
Ueda K, Taguchi Y, Morishima M. How does P-gp recognize its substrates?. Semin Cancer Biol 1997; 8: 151–9PubMed
31.
Taguchi Y, Kino K, Morishima M, et al. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry 1997; 36: 8883–9PubMed
32.
Taguchi Y, Morishima M, Komano T, et al. Amino acid substitutions in the first transmembrane domain (TM1) of P-glycoprotein alter substrate specificity. FEBS Lett 1997; 413: 142–6PubMed
33.
Loo TW, Clarke DM. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem 1994; 269: 7243–8PubMed
34.
Currier SJ, Kane SE, Willingham MC, et al. Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J Biol Chem 1992; 267: 25153–9PubMed
35.
Pan B-F, Dutt A, Nelson JA. Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J Pharmacol Exp Ther 1994; 270: 1–7PubMed
36.
Wu C-Y, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492–7PubMed
37.
Tang-Wai DF, Brossi A, Arnold LD, et al. The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 1993; 32: 6470–6PubMed
38.
Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports Cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248–52PubMed
39.
Chiba P, Holzer W, Landau M, et al. Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity. J Med Chem 1998; 41: 4001–11PubMed
40.
Ecker G, Huber M, Schmid D, et al. The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol 1999; 56: 791–6PubMed
41.
Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31–40PubMed
42.
Seelig A. How does P-glycoprotein recognize its substrates?. Int J Clin Pharmacol Ther 1998; 36: 50–4PubMed
43.
Osterberg T, Norinder U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10: 295–303PubMed
44.
Chiba P, Ecker G, Schmid D, et al. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 1996; 49: 1122–30PubMed
45.
Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41: 535–67PubMed
46.
Lankas GR, Cartwright ME, Umbenhauer DR. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 143: 357–65PubMed
47.
Umbenhauer DR, Lankas GR, Pippert TR, et al. Identification of a P-glycoprotein-deficient subpopulation in CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 1997; 146: 88–94PubMed
48.
Lankas GR, Wise LD, Cartwright ME, et al. Placenta P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998; 12: 457–63PubMed
49.
Pippert TR, Umbenhauer DR. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1agene. J Biochem Mol Toxicol 2001; 15: 83–9PubMed
50.
Pulliam JD, Seward RL, Henry RT, et al. Investigating ivermectin toxicity in Collies. Vet Med 1985; 80: 33–40
51.
Paul AJ, Tranquilli WJ, Seward RL, et al. Clinical observations in Collies given ivermectin orally. Am J Vet Res 1987; 48: 684–5PubMed
52.
Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11: 727–33PubMed
53.
Kioka N, Tsubota J, Kakehi Y, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Glyl85 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989; 162: 224–31PubMed
54.
Mickley LA, Lee J-S, Weng Z, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–56PubMed
55.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–8PubMed
56.
Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotyperelated pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–4PubMed
57.
Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–99PubMed
58.
Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526–34PubMed
59.
von Ahsen N, Fichter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048–52
60.
Min DI, Ellingrod V. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24: 400–4PubMed
61.
Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137–43PubMed
62.
Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169–74PubMed
63.
Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1994; 25: 1–53
64.
Ameyaw M-M, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217–21PubMed
65.
Elmore JG, Moceri VM, Carter D, et al. Breast carcinoma tumor characteristics in black and white women. Cancer 1998; 83: 2509–15PubMed
66.
Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1, and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–84PubMed
67.
Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for P-glycoprotein mediated transport: species difference and predictability of in vitro results. J Pharmacol Exp Ther 2001; 296: 723–35PubMed
68.
Gruol DJ, Vo QD, Zee MC. Profound differences in the transport of steroids by two mouse P-glycoproteins. Biochem Pharmacol 1999; 58: 1191–9PubMed
69.
Devault A, Gros P. Two members of mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 10: 1652–63PubMed
70.
Taylor JC, Ferry DR, Higgins CF, et al. The equilibrium and kinetic drug binding properties of the mouse P-gpla and P-gplb P-glycoproteins are similar. Br J Cancer 1999; 81: 783–9PubMed
71.
Tang-Wai DF, Kajiji S, DiCapua F, et al. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995; 34: 32–9PubMed
72.
Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346–50PubMed
73.
Schuetz EG, Umbenhauer DR, Yasuda K, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdrl genes. Mol Pharm 2000; 57: 188–97
74.
Aungst BJ. Novel formulation strategies for improving oral bioavailability of drug with poor membrane permeation or pre-systemic metabolism. J Pharm Sci 1993; 82: 979–87PubMed
75.
Ho NF, Park JY, Ni PF, et al. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In: Crouthamel W, Sarapu AC, editors. Animal models for oral drug delivery in man: in situ and in vivo approaches. Washington, DC: American Pharmaceutics Association, Academy of Pharmaceutical Sciences, 1983: 27–106
76.
Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 model. Pharm Res 1997; 14: 1210–5PubMed
77.
Creamer B. The turnover of the epithelium of small intestine. Br Med Bull 1967; 23: 226–30PubMed
78.
Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265–9PubMed
79.
Fricker G, Drewe J, Huwyler J, et al. Relevance of P-glycoprotein for the enterai absorption of cyclosporine A: in vitro-in vivo correlation. Br J Pharmacol 1996; 118: 1841–7PubMed
80.
Nakayama A, Saitoh H, Oda M, et al. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 2000; 11: 317–24PubMed
81.
Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248–60PubMed
82.
Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68: 98–103PubMed
83.
Hunter J, Jepson MA, Tsuruo T, et al. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cell layers: kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993; 268: 14991–7PubMed
84.
Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cells. Pharm Res 1993; 10: 743–9PubMed
85.
Augustijins PF, Bradshaw TP, Gan LSL, et al. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem Biophys Res Commun 1993; 197: 360–5
86.
Burton PS, Conradi RA, Hilgers AR, et al. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem Biophys Res Commun 1993; 190: 760–6PubMed
87.
Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94: 2031–5PubMed
88.
Mayer U, Wagnaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrl a P-glycoprotein. Br J Pharmacol 1996; 119: 1038–44PubMed
89.
Israili ZH, Dayton PG. Enhancement of xenobiotic elimination: role of intestinal excretion. Drug Metab Rev 1984; 15: 1123–59PubMed
90.
Meerum Terwgot JM, Malingre MM, Beijnen JH, et al. Co-administration of cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5: 3379–84
91.
Malingre MM, Richel DJ, Beijinen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001; 19: 1160–6PubMed
92.
Bohme M, Buchler M, Muller M, et al. Differential inhibition by cyclosporines of primary-active ATP-dependent transporters in hepatocyte canalicular membrane. FEBS Lett 1993; 333: 193–6PubMed
93.
Stephens RH, O’Neill CA, Warhurst A, et al. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001; 296: 584–91PubMed
94.
Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporine A and FK506. J Biol Chem 1993; 268: 6077–80PubMed
95.
Wetterich U, Sphn-Langguth H, Mutschier E, et al. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 1996; 13: 514–22PubMed
96.
Ueda CT, Lemaire M, Gsell G, et al. Apparent dose dependent oral absorption of cyclosporine A in rats. Biopharm Drug Dispos 1984; 5: 141–51PubMed
97.
Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther 2000; 292: 310–8PubMed
98.
Lin JH. Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev 1999; 39: 33–49PubMed
99.
Chiou WL, Chung SM, Wu TC, et al. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001; 39: 93–101PubMed
100.
Makhey VD, Guo A, Norris DA, et al. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160–7PubMed
101.
Handschumacher RE. Immunosuppressive agents. In: Gilman AG, Palmer T, Nies AS, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York (NY): McGraw-Hill Inc, 1990: 1264–76
102.
Mouritsen OG, Jorgensen K, Honger T. Permeability of lipid bilayers near the phase transition. In: Disalvo EA, Simon SA, editors. Permeability and stability of lipid bilayers. Boca Raton (FL): CRC Press, 1995: 137–60
103.
Eichler H-G, Muller M. Drug distribution: the forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95–9PubMed
104.
Kim RB. Transporters and drug disposition. Curr Opin Drug Discov Devel 2000; 3: 94–101PubMed
105.
Pardridge WM. Transport of protein-bound hormones into tissue in vivo. Endocr Rev 1981; 2: 103–23PubMed
106.
Rapoport SI. Transport in cells and tissues. In: Rapport SI, editor. Blood-brain barrier in physiology and medicine. New York (NY): Raven Press, 1976: 17–42
107.
Chikhale EG, Ng K-Y, Burton PS, et al. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 1994; 11: 412–9PubMed
108.
Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682–4PubMed
109.
Lin TH, Lin JH. Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J Pharmacol Exp Ther 1990; 253: 45–50PubMed
110.
Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159–64PubMed
111.
Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86: 695–8PubMed
112.
Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothe-lium of blood vessels in the brain. Biochem J 1997; 326: 539–44PubMed
113.
Barrand MA, Bennett GC, Taylor CJ, et al. Immunohistochemical localization in rat brain microvessels of transporters involved in solute and water movements across the blood-brain barrier [abstract]. IVth International Conference: Cerebral Vascular Biology, Blood-Brain Barrier; 2001 Apr 1–5; Cambridge, UK
114.
Matsuoka Y, Okazaki M, Kitamura Y, et al. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 1999; 39: 383–92PubMed
115.
Decleves X, Regina A, Laplanche J-L, et al. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res 2000; 60: 594–601PubMed
116.
Pardridge WM, Golden PL, Kang Y-S, et al. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem 1997; 68: 1278–85PubMed
117.
Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000; 20: 165–81PubMed
118.
de Lange ECM, de Bock G, Schinkel AH, et al. BBB transport and P-glycoprotein functionality using mdr1a (−/−) and wild-type mice: total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 1998; 15: 1657–65PubMed
119.
Lee G, Schlichter L, Bendayan M, et al. Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 2001; 299: 204–12PubMed
120.
Chen C, Pollack GM. Altered disposition and antinociception of [D-penicillamine2,5]enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 1998; 287: 545–52PubMed
121.
Tsuji A, Terasaki T, Takabatake Y, et al. P-glycoprotein as the drug efflux pump in the primary cultured bovine brain capillary endothelial cells. Life Sci 1992; 51: 1427–37PubMed
122.
Tatsuta T, Naito M, Ohhara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383–91PubMed
123.
Tsuji A, Tamai I, Sakata A, et al. Restricted transport of cyclosporine A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993; 46: 1096–9PubMed
124.
Shirai A, Naito M, Tatsuta T, et al. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1994; 1222: 400–4PubMed
125.
Biegel D, Spencer DD, Pachter JS, et al. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res 1995; 692: 183–9PubMed
126.
Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992; 102: 879–85PubMed
127.
Kamimoto Y, Gatmaitan Z, Hsu J, et al. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biochem Chem 1989; 264: 11693–8
128.
Ohnishi T, Tamai I, Sakanaka K, et al. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995; 49: 1541–4PubMed
129.
Sakata A, Tamai I, Kawazu K, et al. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol 1994; 48: 1989–92PubMed
130.
Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698–705PubMed
131.
Schinkel AH, Mol CAAM, Wagenaar E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995; 31A: 1295–8PubMed
132.
Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrla knockout mice. Pharm Res 1999; 16: 1213–8PubMed
133.
Smit JW, Huisman MT, van Teilingen O, et al. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999; 104: 1441–7PubMed
134.
Nakamura Y, Ikeda S, Furukawa T, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 1997; 235: 849–53PubMed
135.
Ushigome F, Takanaga H, Matsuo H, et al. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur J Pharmacol 2000; 408: 1–10PubMed
136.
Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–60PubMed
137.
Debri K, Boobis AR, Davis DS, et al. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 1995; 50: 2047–56PubMed
138.
Watkins PB, Murray SA, Thomas PE, et al. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. Biochem Pharmacol 1990; 39: 471–6PubMed
139.
Murray GI, Barnes TS, Sewell HF, et al. The immunochemical localisation and distribution of cytochrome P-450 in normal hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 1988; 25: 465–75PubMed
140.
Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27: 99–127PubMed
141.
Hochman JH, Chiba M, Yamazaki M, et al. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther 2001; 298: 323–30PubMed
142.
Gan L-SL, Moseley MA, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996; 24: 344–9PubMed
143.
Lin JH, Chiba M, Chen I-W, et al. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3 A and P-glycoprotein induction. Drug Metab Dispos 1999; 27: 1187–93PubMed
144.
Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol Rev 1999; 51: 135–57PubMed
145.
Meijer DKF, Smit JW, Muller M. Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters. Adv Drug Deliv Rev 1997; 25: 159–200
146.
Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. J Membr Biol 1999; 167: 103–17PubMed
147.
Watanabe T, Miyauchi S, Sawada Y, et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 1992; 16: 77–88PubMed
148.
Ballet F, Vrignaud P, Robert J, et al. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 1987; 19: 240–5PubMed
149.
Kawahara M, Sakata A, Miyashita T, et al. Physiologically based pharmacokinetics of digoxin in mdrla knockout mice. J Pharm Sci 1999; 88: 1281–7PubMed
150.
van Asperen J, van Teilingen O, Beijnen JH. The role of mdrla P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 2000; 28: 264–7PubMed
151.
Smit JW, Schinkel AH, Muller M, et al. Contribution of the murine mdrla P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdrla gene disruption. Hepatology 1998; 27: 1056–63PubMed
152.
Smit JW, Schinkel AH, Weert B, et al. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdrla and mdr1b genes have been disrupted. Br J Pharmacol 1998; 124: 416–24PubMed
153.
Okamura N, Hirai M, Tanigawara Y, et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993; 266: 1614–9PubMed
154.
Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992; 263: 840–5PubMed
155.
Horio M, Chin K-V, Currier SJ, et al. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989; 264: 14880–4PubMed
156.
Hori R, Okamura N, Aiba T, et al. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266: 1620–5PubMed
157.
De Lannoy IAM, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992; 263: F613–22PubMed
158.
van Asperen J, van Tellinge O, Tijssen F, et al. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdrla P-glycoprotein. Br J Cancer 1999; 79: 108–13PubMed
159.
Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361–90PubMed
160.
Ronis MJJ, Ingelman-Sundberg M. Induction of human drugmetabolizing enzymes: mechanism and implications. In: Woolf TF, editor. Handbook of drug metabolism. New York (NY): Marcel Dekker Inc, 1999: 239–62
161.
Lazarou J, Pomeraanz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5PubMed
162.
Duchateau AMJA. Posicor: veni, vidi, foetsie. Pharm Weekbl 1998; 133: 1294–5
163.
Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 1996; 32A: 991–1001PubMed
164.
Tamai I, Safa AR. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991; 266: 16796–800PubMed
165.
Ramachandra M, Ambudkar SV, Chen D, et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 1998; 37: 5010–9PubMed
166.
Senior AE, Al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. FEBS Lett 1995; 377: 285–9PubMed
167.
Ayesh S, Shao Y-M, Stein WD. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1996; 1316: 8–18PubMed
168.
Tamai I, Safa AR. Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J Biol Chem 1990; 265: 16509–13PubMed
169.
Callaghan R, Riordan JR. Synthetic and nature opiates interact with P-glycoprotein in multidrug resistant cells. J Biol Chem 1993; 268: 16059–64PubMed
170.
Litman T, Zeuthen T, Skovsgaard T, et al. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1997; 1361: 169–76PubMed
171.
Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 1998; 333: 351–8PubMed
172.
Critchfield JW, Welsh CJ, Phang JM, et al. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Biochem Pharmacol 1994; 48: 1437–45PubMed
173.
Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997; 250: 130–7PubMed
174.
Houston JB, Kenworthy KE. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 2000; 28: 246–54PubMed
175.
Wang RW, Newton DJ, Liu N, et al. Human cytochrome P450 3A4; in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 2000; 28: 360–6PubMed
176.
Shou M, Mei Q, Ettore MW, et al. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 1999; 340: 845–53PubMed
177.
Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944–8PubMed
178.
Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655–60PubMed
179.
Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16: 1206–12PubMed
180.
Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430–6PubMed
181.
Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231–7PubMed
182.
Verschraagen M, Koks CHW, Schellens JHM, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40: 301–6PubMed
183.
Bussey HI. The influence of quinidine and other agents on digitalis glycosides. Am Heart J 1982; 104: 289–302PubMed
184.
Mordel A, Halkin H, Zulty L, et al. Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 1993; 53: 457–62PubMed
185.
Pedersen KE. Digoxin interaction: the influence of quinidine and verapamil on pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand 1985; 697: 11–40
186.
Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991; 13: 381–401PubMed
187.
Sababi M, Borga O, Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 2001; 14: 21–7PubMed
188.
Su FG, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142–7PubMed
189.
Tsuruo T, Lida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–72PubMed
190.
Advani R, Fisher GA, Lum BL, et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC833), a modulator of multidrug resistance. Clin Cancer Res 2001; 7: 1221–9PubMed
191.
Sparreboom A, St Planting A, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999; 10: 719–28PubMed
192.
van Zuylen L, Nooter K, Sparreboom A, et al. Development of multidrug resistance convertors: sense or nonsense?. Invest New Drugs 2000; 18: 205–20PubMed
193.
Johannessen A, Rendtorff C, Poulsen S. Digoxin intoxication induced by verapamil in an uremic patient. Clin Nephrol 1985; 24: 158–9PubMed
194.
Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982; 65: 998–1003PubMed
195.
Fardel O, Lecureur V, Corlu A, et al. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methycholanthrene treatment. Biochem Pharmacol 1996; 51: 1427–36PubMed
196.
Chin KV, Chauhan SS, Pastan I, et al. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1: 361–5PubMed
197.
LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001; 134: 283–9PubMed
198.
Fardel O, Lecureur V, Guillouzo A. Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 1993; 327: 189–93PubMed
199.
Zhao JY, Ikeguchi M, Eckersberg T, et al. Modulation of multi-drug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 1993; 133: 521–8PubMed
200.
Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998; 55: 387–95PubMed
201.
Liu J, Brunner LJ. Chronic cyclosporine administration induces renal P-glycoprotein in rats. Eur J Pharmacol 2001; 418: 127–32PubMed
202.
Jette L, Beaulieu E, Leclerc J-M, et al. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270: F756–65PubMed
203.
Lee CH. Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated. Mol Cell Biochem 2001; 216: 103–10PubMed
204.
Durr D, Stieger B, Kullak-Ublick GA, et al. St. John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598–604PubMed
205.
Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P450 3 A coordinately up-regulated these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311–8PubMed
206.
Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures human hepatocytes. Mol Pharmacol 1992; 41: 1047–55PubMed
207.
Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–34PubMed
208.
Callen DF, Baker E, Simmers RN, et al. Localization of the human multidrug resistance gene, MDR1, to 7q21.1. Hum Genet 1987; 77: 142–4PubMed
209.
Inoue K, Inazawa J, Nakagawa H, et al. Assignment of the human cytochrome P450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn J Hum Genet 1992; 37: 133–8PubMed
210.
Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001; 29: 615–22PubMed
211.
Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27–39PubMed
212.
Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic—sensing nuclear receptor. Genes Dev 1998; 12: 3195–205PubMed
213.
Moore LB, Goodwin B, Jones SA, et al. St. John’s Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500–2PubMed
214.
Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 2001; 7: 584–90PubMed
215.
Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581–7PubMed
216.
Masuyama H, Hiramatsu Y, Mizutani Y, et al. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1 in prenatal mouse. Mol Cell Endocrinol 2001; 172: 47–56PubMed
217.
Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMed
218.
Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114–21PubMed
219.
Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of MDL16,455A in healthy male volunteers [abstract]. Pharm Res 1999; 12: S390
220.
Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71PubMed
221.
Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453–7PubMed
222.
Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322–30PubMed
Metadata
Title
Role of P-Glycoprotein in Pharmacokinetics
Clinical Implications
Authors
Dr Jiunn H. Lin
Masayo Yamazaki
Publication date
01-01-2003
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 1/2003
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342010-00003